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A B S T R A C T
Central hypothyroidism (CH) is a rare cause of hypothyroidism. CH is frequently overlooked, as its clinical
picture is subtle and includes non-specific symptoms; furthermore, if measurement of TSH alone is used to screen
for thyroid function, TSH concentrations can be normal or even above the upper normal reference limit. Indeed,
certain patients are at risk of developing CH, such as those with a pituitary adenoma or hypophysitis, those who
have been treated for a childhood malignancy, have suffered a head trauma, sub-arachnoid hemorrhage or
meningitis, and those who are on drugs capable to reduce TSH secretion.
Introduction
Central hypothyroidism (CH) is a rare cause of hypothyroidism,
since it is reported to occur in 1:16,000 to 1:120,000 individuals [1].
The aim of our review is to show that acquired CH is not an exceedingly
rare entity and that, within anterior hypopituitarism, TSH deficiency is
not so rare either. The corresponding aim for congenital CH is ad-
dressed in an accompanying review [114].
Diagnosis
CH includes hypothyroidism caused by altered secretion of thyro-
tropin (TSH) (secondary hypothyroidism) or TSH-releasing hormone
(TRH) (tertiary hypothyroidism). CH may occur after birth (acquired
CH) or prenatally (congenital CH). In the majority of patients, CH is
combined with other pituitary deficiencies (multiple pituitary hormone
deficiencies to panhypopituitarism). Acquired CH may result from dif-
ferent conditions that ultimately lead to disruption of the hypotha-
lamus-pituitary-thyroid axis, such as trauma, tumors, inflammation,
infections and drugs [1,2]. Even if TSH isoforms are qualitatively de-
fective and display impaired biological activity, they can be quantita-
tively normal or even elevated, and maintain their immunoreactivity
[3]. Therefore, serum TSH concentrations in patients with CH may be
low, normal or even above normal, in the face of low free thyroxine
(FT4) concentrations [4]. Measurement of FT4 in turn is also a big
challenge with the current use of the manufacturers' different platforms
most of which are not mutually calibrated and with very different
confounders giving rise to an inherent imperfection of all these mea-
surements [4]. Symptoms and signs of CH, such as fatigue, depression,
and drowsiness are nonspecific and usually milder than seen in primary
hypothyroidism, and they can be confused with those ascribed to de-
ficiency of other pituitary tropins or even other hormonal and non-
hormonal diseases. Thus, because the clinical picture is non-specific and
subtle, the diagnosis of CH is frequently delayed [1,2].
Though limited in size, a study from the Waikato region of New
Zealand of an initial cohort of 20 patients with CH is quite informative
about the delayed diagnosis of CH and the limited recognition by
general practitioners that a normal TSH concentration does not exclude
the diagnosis of CH [5]. The study was based on a questionnaire
completed by 16/20 patients with CH (median age at diagnosis
58 years, range 35–80). Both TSH and T4 were measured in 81% (13/
16) of the participants prior to their first endocrine assessment, and
75% (12/16) had results suggesting pituitary disease [5]. Seven parti-
cipants (44%) had symptoms (e.g. headaches, lethargy, visual dis-
turbances, and weight- and mood changes) for more than one year and
another 6 (38%) for more than 2 years. Time to diagnosis ranged from 3
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to more than 12months, and 7 participants had 3–6 visits, and 5 had
6–12 visits to their general practitioner prior to diagnosis [5].
Prevalence
Both textbooks and papers provide information that CH is (very)
rare, ranging from 1:16,000 to 1:120,000 [1,6–10]. CH has also been
described to occur in fewer than 1% of hypothyroid patients or being
about 1000-fold rarer than primary hypothyroidism [2,6–10]. How-
ever, an important English paper challenged this widely held opinion
about the rarity of CH [11]. Using a combination of TSH and FT4 assays
in lieu of the standard TSH alone assay, the authors searched for CH in
56,000 Liverpool inhabitants over 12months. They found that 17 pa-
tients had possible CH with normal TSH [11]. Further investigations
found that two of the 17 patients had non-thyroidal illness and the
remaining 15 patients had hypopituitarism, which had not been sus-
pected clinically. During the same 12-month period, 11 patients were
referred to the same hospital on clinical grounds, and hypopituitarism
was confirmed [11]. Extrapolation to the Liverpool population of
471,000 suggested an incidence of CH of 55 cases/million/year, of
which 32/million/year might be undiagnosed, in the face of previously
reported incidence of CH of 8–9 adult cases/million/year [12].
Over the same 12-month period, the ratio of primary to secondary
hypothyroidism detected by the above test strategy was 20:1 [11]. Such
20:1 ratio of primary to secondary hypothyroidism [11] might appear
grossly overestimated in view of the aforementioned widely held opi-
nion on the rarity of CH [9]. However, the 20:1 ratio is consistent with
what can easily be calculated based on a recent meta-analysis [13]: the
incidence of hypothyroidism in Europe is 226 per 100,000 per year,
which divided by 5.5/100,000 (incidence of CH according to Wardle
et al. [11]) equals 41: 1.
In a Spanish study, the frequency of diagnosed hypopituitarism was
significantly higher in the year 1999 (45.5/100,000/year) compared to
year 1992 (29/100,000/year), but with similar distribution of etiolo-
gies: pituitary tumors accounting for around 60%, extrapituitary tumors
for 10%, and non-tumoral causes for approximately 30% [14]. Thus, in
1999 the incidence of CH from non-tumoral causes was 10/100,000/
year, which is again an order of magnitude similar to the incidence of
CH according to Wardle et al. [11].
Methods
A systematic literature search using PubMed and MEDLINE data-
bases was performed using the strings “acquired central hypothyr-
oidism”, “central hypothyroidism AND traumatic brain injury”, “central
hypothyroidism AND subarachnoid hemorrhage”, “central hypothyr-
oidism AND primary hypophysitis”, “central hypothyroidism AND pi-
tuitary adenoma”, “central hypothyroidism AND childhood
malignancy”, “central hypothyroidism AND childhood brain tumor”,
“central hypothyroidism AND meningitis”, “central hypothyroidism
AND infiltrative disorders”, “central hypothyroidism AND drugs”.
Results
Traumatic brain injury (TBI)
The incidence of 5.5/100,000/year for CH [11] may be an under-
estimate as hypopituitarism secondary to high-incidence conditions
might not have been taken into consideration. In the last decade there
has been increased attention to hypopituitarism as a complication of
traumatic brain injury (TBI) [15]. TBI leading to hospitalization has an
incidence of 100–350 per 100,000 in the general population [15–19].
Relatively few cases are fatal; most individuals survive long-term, some
of whom continue to suffer from non-specific symptoms such as de-
pression, fatigue, sexual disturbances, cognitive deficits and sleep dis-
orders [20,21]. More recent studies have reported a high prevalence of
chronic anterior pituitary hormone deficiency following TBI with an
estimated frequency of more than 25% (approximately 5% for CH)
(Table 1) [17].
Since single axis failure was most often reported, some authors have
questioned the quality of the diagnostic work-up in patients with TBI
and, therefore, the related prevalence [18]. Pituitary assessment is
generally restricted to patients at risk of hypopituitarism, such as those
with hypothalamus-pituitary disease or those who underwent pituitary
surgery or brain irradiation, who are referred to tertiary care en-
docrinology centers. However, making diagnosis of hypopituitarism in
patients with non-classical causes of hypopituitarism is challenging.
Moreover, the diagnosis is even more challenging in light of false po-
sitive tests and gray-zone results for each pituitary hormone [18,22].
Laboratory results should be interpreted in light of clinical features and
pretest probability [23], as post-TBI single axis failure can occur [18].
Gonadotropin and GH deficiencies may be misinterpreted because of
confounders. One confounder is obesity, since it decreases sex hor-
mone-binding globulin levels and GH response during stimulation tests
[18,22].
With a TBI incidence of 100–350 per 100,000 persons/year [15–19]
and assuming a 5% frequency of post-TBI CH (Table 1), the resulting
incidence of post-TBI CH would approximate 40 per 100,000 persons/
year. As the incidence of primary hypothyroidism in Europe is 226 per
100,000 in the general population [13], the primary hypothyroidism to
CH ratio would be 226:40, or 5.6:1. The ratio would be even lower in
the pediatric setting, given that deficiency of TSH is as frequent as
deficiency of other anterior pituitary hormones among children and
adolescents with post-TBI hypopituitarism [19]. In this review of 10
studies, addressing post-traumatic hypopituitarism in 20 pediatric case
reports, CH occurred in 75% of subjects, whereas GH deficiency, central
Table 1
Systematic reviews and meta-analysis including studies on anterior hypopituitarism-induced by traumatic brain injury and subarachnoid hemorrhage. Frequency of
pituitary deficit is reported as range of percent values.
Author [ref] Any TSH ACTH GH FSH and/or LH
SAH (n=102) Schneider et al. [17] 37.5–55 2.5–9.4 6.3–40 20–6.7 0–13.3
SAH (n=691) Khajeh et al. [30] 0–55 0–20 0–40 0–37 0–28
SAH (n=924) Can et al. [32] (3–6months) 4.5–37.5 0–9.3 0–28.1 0–25 0–23.6
Can et al. [32] (> 6months) 0–55 0–13.3 0–40 0–36.7 0–36.7
SAH (n=110) Valdes-Socin [33] N/A 2.5–7.5 2.5–32 12.5–37 0–13
TBI (n= 809) Schneider et al. [17] 15.4–50 1–13.2 0–19.2 5.9–32.7 1.9–20
TBI, children & adolescents (n= 20) Acerini et al. [19] N/A 50–100 0–100 50–100 66.7–100
Abbreviations: ACTH=adrenocorticotropic hormone; GH=growth hormone; FSH= follicle-stimulating hormone; LH= luteinizing hormone; TBI= traumatic
brain injury; TSH= thyroid-stimulating hormone; SAH= subarachnoid hemorrhage.
All studies reviewed by Acerini et al. [19] are case reports of post-head trauma hypopituitarism, as opposed to screening studies. Accordingly, it is inappropriate to
calculate rate of deficiency for at least one anterior pituitary hormone. The percentages of hormone deficits in the Acerini et al. paper are distribution among the 20
cases of post-head trauma hypopituitarism.
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hypogonadism and central hypoadrenalism were seen in 85%, 80% and
55%, respectively (Table 1) [19]. In another small series of 15 patients
with post-TBI CH (7 men, age at CH diagnosis 50 years, range 19–68,
and age at trauma 30 years, range 7–59) [24], 3/15 (20%) had isolated
CH whereas coexisting deficiencies occurred at the following rates: 60%
(gonadotropins), 47% (GH), 27% (ACTH), 13% (PRL). One patient had
panhypopituitarism [24].
Subarachnoid hemorrhage (SAH)
With an incidence of 10.5 per 10,000 persons/year in Western
Europe, SAH is 10–30 times less incident than TBI. SAH results from
ruptured aneurysm, perimesenchephalic hemorrhage and rare condi-
tions in 85%, 15% and 15% of the cases, respectively. Fatal cases of
SAH range from 32 to 67%, and in one-third of nonfatal cases disability
is a permanent sequela [25]. Similar to TBI, aneurysmal SAH can pose a
risk to pituitary function, because of the vulnerable vascular supply of
pituitary and the delicate infundibular-hypothalamic structures
[26–28]. However, investigations on SAH-induced hypopituitarism are
more limited compared to TBI and have never addressed the effects of
SAH per se on the pituitary [26]. Compression of the pituitary gland by
the aneurysm, changes in tissue pressure post-hemorrhage, hydro-
cephalus, increased intracranial pressure and vasospam-induced
ischemia have been proposed as mechanisms for the pituitary damage
[26]. The majority of these studies [15,16,19,21,24] have taken into
account series of patients after either SAH or TBI [20]. The high het-
erogeneity of results (Table 1) stems from differences in follow-up and
in methods and thresholds used to evaluate endocrine function.
Nevertheless, CH is one of the rarest deficit as opposed to GH deficiency
[29,30].
One review [30] included 16 studies published between 1995 and
2014 and prospective (10 studies) or cross-sectional/retrospective (6
studies) evaluation of pituitary function in the long term. The study
populations ranged from 10 to 93 patients, with an interval between
SAH and endocrine assessment from 3months to 10 years. Endocrine
function was evaluated basally and, in 12 studies, dynamically. CH
occurred in no patient in 6 studies, whereas in the remaining 10 its
frequency ranged from 2% to 20% [30]. In particular, in the study that
reported the highest frequency (20%) of CH, this deficit was the most
prevalent in the ten patients evaluated except for testosterone defi-
ciency (30%) [31] (Table 1). The systematic review by Schneider
confirmed that SAH was associated with a higher frequency of hypo-
pituitarism compared with TBI [17]. Recently, Can et al. reviewed and
meta-analyzed 17 studies on SAH-induced hypopituitarism at
3–6months and > 6months after the hemorrhagic event [32]. The
pooled frequency of CH was the same at 3–6months and > 6months
(0.04 [95%CI 0.02–0.08] and 0.04 [95%CI 0.02–0.07], respectively),
whereas, frequencies of central hypogonadism, diabetes insipidus and
multiple pituitary deficiencies decreased over time, although this dif-
ference was not significant [32]. Finally, in a French-language review of
three retrospective studies, post-SAH CH was reported in 6% of cases,
with a range of 2.5–7% [33].
Primary hypophysitis
TSH deficiency (and therefore CH) is also frequent in primary hy-
pophysitis [34] (Table 2), which is an autoimmune inflammation of the
pituitary gland not caused by drugs or microbes (see 3.6. Meningitis
and 3.7. Drugs). Primary hypophysitis is a truly rare pathology of the
pituitary with an annual incidence between 0.1 and 0.9/100,000 [34].
Based on the extension of lymphocytic infiltrate, three forms are
identified: panhypophysitis, adenohypophysitis and infundibulo-neu-
rohypophysitis [35]. Five histologically different variants are dis-
tinguished: lymphocytic, granulomatous, xanthomatous, necrotizing
and IgG-related. Lymphocytic hypophysitis is by far the most common
variant [35,36]. Finally, IgG4-related hypophysitis with IgG4-positive
plasma cells infiltrating the pituitary has been recently described [37].
In a German nationwide retrospective study [34], 66 patients with
primary hypophysitis were identified. Central hypogonadism and GH
deficiency were the most and the least frequent endocrine disturbances,
with a frequency of 62% and 37%, respectively. CH occurred in around
half of patients (48%), with a higher, but insignificant, frequency in
histologically confirmed cases of hypophysitis compared to those not
confirmed by histology [34]. Recently, in a prospective single-center
study, 3/21 (14.3%) patients with primary hypophysitis had CH [38]
(Table 2).
Pituitary adenomas
Hypopituitarism, and therefore CH, may result from pituitary ade-
nomas and radiotherapy and surgery thereof. Less frequently, CH may
result from pituitary apoplexy [39]. Macroadenomas, i.e. tumors larger
than 1 cm, cause hypopituitarism by increasing intrasellar pressure and
compressing blood supply, and consequently, interrupting delivery of
hypothalamic hormones to the anterior pituitary. Increased intrasellar
pressure is considered a major factor determining hypopituitarism,
hyperprolactinemia and headache [40]. However, tumor size does not
correlate with either mean intrasellar pressure or prolactin levels [40].
The Endocrine Society recommends testing all patients with pituitary
adenomas for hypopituitarism, irrespective of tumor size [41]. It is still
debated whether CH screening should include FT4 alone or FT4 plus
TSH [41]. CH together with central hypoadrenalism, is the least fre-
quent pituitary deficit, as it occurs in up to one-third of patients with
pituitary incidentaloma, that is a previously unsuspected pituitary le-
sion incidentally discovered on imaging study [41].
In a Brazilian retrospective study on 104 patients with non-func-
tioning pituitary adenoma, almost completely sized > 1 cm (macro-
adenoma, 93%), CH was observed in 20.4% of cases [42]. This rate
matched well with that found in an Italian study (24.5%), which ana-
lyzed 295 patients with non-functioning pituitary adenoma (96.5% of
which macroadenoma) [43]. Nevertheless, in another retrospective
study, the frequency of inappropriately normal TSH with thyroid hor-
mone levels below the normal reference range (i.e. CH) was 16% in 61
patients with pituitary incidentaloma (one-fifth being≤ 1 cm) [44].
Within microadenomas, ACTH-secreting tumors have higher pre-
valence of hypothyroidism compared with either nonfunctioning or
other hormone-secreting microadenomas [45]. ACTH-secreting ade-
nomas are rare with an incidence of approximately 0.3/100,000/year
[46], and a retrospective study [45] demonstrated that CH was present
in 6/34 (17.6%), micro-prolactinomas and nonfunctioning
Table 2
Frequency of pituitary deficit reported in patients with either hypophysitis.
Author
[ref]
Any TSH ACTH GH FSH
and/
or LH
Hypophysitis (n= 66) Honegger
et al. [34]
? 48 47 37 62
Histologically proven (n=33) ? 64 52 40 70
Lymphocytic (n= 24) ? 57 48 41 57
Granulomatous (n= 9) ? 88 63 38 100
Hypophysitis (n= 21) Chiloiro
et al. [38]
Adenohypophysitis (n=9) 29 0 19 0 9
Panhypophysitis (n=4) 14 5 9 0 5
Infundibuloneurohypophysitis
(n= 8)
33 9 5 24 29
Abbreviations: ACTH= adrenocorticotropic hormone; GH=growth hormone;
FSH= follicle-stimulating hormone; LH= luteinizing hormone;
TSH= thyroid-stimulating hormone.
Rate of deficiency for at least one anterior pituitary hormone was not provided
by Honneger et al. [34], nor cannot be calculate by the data provided.
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microadenomas had 1/72 (1.4%) and 0/43 cases of CH, respectively.
This difference corresponded to an odds ratio of 11.3 of CH (95% CI
2.169-58.87) in ACTH-microadenomas compared to non-ACTH ade-
nomas of comparable size. In addition, normalized FT4 was sig-
nificantly lower in the ACTH group than in the non-ACTH group [45].
The TSH-suppressive effect of cortisol may at least in part explain these
results, although neither TSH nor FT4 concentrations correlated with
the degree of hypercortisolism as measured by urinary free cortisol and
salivary cortisol [45]. However, numbers were small and did not have
sufficient power for calculating such correlations.
While CH is unusual following selective removal of a pituitary mi-
croadenoma, it is relatively more frequent (< 10%) after macro-
adenoma excision [47]. Concerning radiotherapy, Brada et al. esti-
mated at 30% the probability of receiving either thyroxine or
corticosteroid replacement at 10 years after conventional external-
beam radiotherapy [48]. Recent advances in radiation treatment of
pituitary adenomas have reduced long-term endocrine complications.
Stereotactic surgery, which consists of a single-session, highly precise
delivery of radiation to one lesion, can be performed either by gamma-
knife surgery or other stereotactic modalities. For instance, Sicignano
et al. followed up 130 patients treated with gamma-knife surgery (at
least 15 Gy for non-functioning pituitary adenomas, at least 25 Gy for
secreting pituitary adenomas) for more than 6months (median
60months) [49]. During the follow-up, 8/113 (7.1%) patients who had
normal baseline thyroid function, developed hypothyroidism, whereas
9/93 patients (9.7%) who had normal baseline thyroid and adrenal
function, developed hypothyroidism and/or hypoadrenalism [49].
Survivors of childhood brain tumors and other childhood malignancies
As summarized in a recent article [50], central nervous system tu-
mors (CNS) are the second most common malignancies of childhood
with over 3500 annual cases diagnosed in the United States. Modern
treatment protocols have resulted in>70% of children with CNS tu-
mors becoming long-term survivors, so that as of 2005, it was estimated
that there were>50,000 survivors of pediatric central nervous system
tumors in the US. One multi-institutional study comprehensively de-
scribed late effects in 21 survivors treated in the Head Start I/II pro-
tocols [50]. Among late effects (frequency; median time of onset since
diagnosis), GH (48%; 4.7 years) and TSH deficiencies (33%; 4 years)
were seen. None of the 10 irradiation-free survivors was diagnosed with
CH as opposed with 7/11 irradiated survivors (P=0.004) [50]
(Table 3).
In a questionnaire-based study in 1607 adults who survived for 5 or
more years from childhood brain tumors and 3418 controls, GH and
gonadotropin deficiencies were much more frequent than CH, as the
corresponding relative risks were 278, 86 and 14, respectively [51].
Among patients with medulloblastoma/PNET and ependymoma treated
with a combination of surgery, chemotherapy and irradiation, the in-
cidence of GH deficiency or CH ranged from 0 to 53% and from 0 to
47%, respectively, depending on treatment(s). This study concluded
that childhood brain tumor survivors are at a significantly increased
risk for several adverse endocrine consequences [51]. However, a study
of 6 patients treated for acute lymphoblastic leukemia with che-
motherapy alone found 2 (33%) with CH [52]. Based on a literature
review of 22 studies on childhood brain tumor survivors, the most
commonly reported endocrine disorder within the first 5 years after
diagnosis was GH deficiency (range 13–100%), followed by primary
gonadal dysfunction (0–91%), CH (0–67%) and primary/subclinical
hypothyroidism (range 0–64%) [53].
A study at Memorial Sloan-Kettering, New York, evaluated endo-
crine consequences in a cohort of 88 children with embryonal brain
tumors treated with risk-adapted craniospinal irradiation, conformal
primary site irradiation, and high-dose chemotherapy [54]. The cu-
mulative incidence of GH deficiency, ACTH deficiency, CH and primary
hypothyroidism at 4 years from diagnosis was 93%, 38%, 23%, and
65%, respectively. Radiation dosimetry to the hypothalamo-pituitary
axis was associated only with the development of CH. Particularly, the
median dose to the hypothalamus was higher in patients who devel-
oped CH compared with patients who did not (50.1 vs 40.7 Gy, re-
spectively) [54].
In a Lithuanian study of 51 children treated for low-grade glioma
and medulloblastoma with surgery, radiotherapy, chemotherapy or
combined treatment, CH was observed in 25.9% of patients, and was
significantly more prevalent in patients who were treated with radio-
therapy compared with those who were not (41.2% vs. 0%, P= 0.045)
[55]. The cumulative incidence of CH was 33.7% at 24months, and
remained unchanged 5 years after the end of treatment [55].
A British registry study [49] asked 10,483 childhood cancer survi-
vors if they had been diagnosed with hypothyroidism. Eight percent of
patients reported such diagnosis (etiology not specified), with the
highest risk among Hodgkin lymphoma survivors and those who had
been treated with radiotherapy [56].
In a Danish study of 71 survivors of childhood brain tumors treated
with surgery, radiotherapy and chemotherapy, the rate of primary hy-
pothyroidism was four-fold greater compared to CH (24% vs. 6%) [57].
Survivors who underwent cranial irradiation had a similar rate of pri-
mary hypothyroidism and CH (12% and 9%, respectively), whereas
those who underwent craniospinal irradiation experienced only pri-
mary hypothyroidism (41%) [57]. In another Danish study [58], 95
survivors of childhood acute lymphoblastic leukemia who underwent
chemotherapy either alone (n= 57) or combined with cranial irradia-
tion (n= 38) were challenged with three to five μg of TRH per kg in-
travenously. The authors concluded that a TRH test did not contribute
to the diagnosis of CH [58]. Another study published four years later
confirmed the limited utility of TSH surge after TRH challenge to detect
CH in childhood tumors survivors [59]. However, the results of the TRH
test in 37 survivors after cranial irradiation for childhood tumors and
33 matched controls demonstrated abnormalities in TSH dynamics of
survivors representing subtle alteration of hypothalamus-pituitary-
thyroid axis consisting of a shift in the timing of the peak and/or nadir
TSH and not an actual loss of TSH diurnal rhythm [59].
The rate of hypothyroidism (either primary failure or CH) in 205
survivors of childhood cancers from a Dutch study [60], did not depend
on the applied treatment. A history of brain tumor was the only pre-
dictor for CH in the multivariate analysis [60].
Finally, a recent review showed that cranial irradiation
with≥ 30 Gy, total body irradiation and surgery or tumor in supra-
sellar region are all risk factors for developing CH and other pituitary
deficits [61].
Meningitis
The incidence of meningitis is ten-fold higher in developing than in
developed countries. The incidence of neonatal bacterial meningitis is
0.25–1 case per 1000 live births and higher in premature births (2.5
cases per 1000) compared to 0.15 cases per 1000 full-term births.
Aseptic meningitis, of which viruses are the major cause, has a reported
incidence of 10.9 cases per 100,000 persons/year [62].
Two studies investigated pituitary function months to a couple of
years after an infectious disease of the central nervous system [63,64].
One of them [63] evaluated a total of 19 patients with previous neu-
roborreliosis (n= 4), encephalitis (n= 2), or meningitis (n= 13) fol-
lowing an interval between 10 and 56months (mean 26.1months) after
the acute event. They were 22–65 years old (mean 38.7 ± 11.7 years).
Four patients (21%) showed isolated ACTH insufficiency (peak cor-
tisol < 496.6 nmol/L during an insulin tolerance test), two (10%)
showed borderline gonadotropin insufficiency, but none had GH or TSH
insufficiency nor evidence of diabetes insipidus. The clinical picture of
such patients with endocrine abnormalities might be misinterpreted as
post-encephalitic syndrome [63]. In the other study [64], 14 children
(3.8 years, range 0.03months to 15.8 years), previously hospitalized
S. Benvenga et al. Journal of Clinical & Translational Endocrinology 14 (2018) 25–33
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due to meningitis, were evaluated 2.7 ± 1.2 years after the acute event
with measurement of basal TSH, FT4, cortisol and insulin growth
factor-1 (IGF-1). All the axes evaluated were normal. Only one child
had low height but showed a normal response to a GH stimulation test
[64].
One prospective study assessed pituitary function, anti-pituitary
antibodies and anti-hypothalamus antibodies in 16 adults aged
40.9 ± 15.9 years with acute bacterial or viral meningitis, during the
acute phase and at 6 and 12months after the acute phase [65]. The
rates of GH, ACTH, gonadotrophin and TSH deficiencies were 19%,
12%, 12% and 0% in the acute phase, respectively. At 12months the
corresponding rates were 43%, 7%, 7%, 0%. The rate of isolated defi-
ciencies was two-fold greater compared with combined deficiency (29%
vs. 14%) [65]. Importantly, 44% of hormone deficiencies at 6months
recovered at 12months, whereas 37% appeared de novo at 12months.
Finally, up to half of the patients were positive for anti-pituitary anti-
bodies and anti-hypothalamus antibodies throughout the follow-up
[65]. However, this has not been confirmed by other research groups.
Another study enrolled 19 children with a history of infectious
meningitis at an average age of 4.3 years [66]. Eighteen ± 10months
from the infectious meningitis, none of the subjects had CH, nor other
axis deficits. Thus, the authors concluded that hypopituitarism is an
infrequent complication in children after infectious meningitis [66].
However, the literature reports cases of CH in neonates (almost always
accompanied by other deficiencies) [67,68] and even panhypopitui-
tarism [69–73] as a complication of bacterial meningitis.
Few studies focused on the relationship between meningitis and
hypopituitarism from the opposite perspective. For instance, in a cohort
of 230 evaluable hypopituitary patients, 2 had post-meningitis hypo-
pituitarism, one of whom had CH [74]. Thus, post-meningitis CH ac-
counted for 0.4% of the 211 cases of hypopituitarism.
Of interest, past history of meningitis has been reported in patients
with the very rare Dyke-Davidoff-Masson syndrome (DDMS) in whom
an endocrine evaluation was [75,76] or was not performed [77] [cross
ref – Central Hypothyroidism, Part II, Ref: JCTE_2018_65].
Other inflammatory/infiltrative disorders
The pituitary may be also involved in a number of inflammatory/
granulomatous diseases, which include idiopathic diseases (such as
giant cell hypophysitis), systemic diseases (such as sarcoidosis,
Wegener’s granulomatosis, Takayasu’s disease and Cogan’s syndrome),
and systemic hystiocytosis (such as Langerhans’ cell histiocytosis and
Erdheim-Chester disease) [78]. Symptoms encompass headache, cranial
neuropathy, mental changes, visual disturbance and hydrocephalus.
Also, within hypopituitarism, CH may occur with variable prevalence
[78].
Sarcoidosis is a chronic disorder with multisystemic deposition of
epitheliod granulomas. Its etiology is still unknown. In up to 15% of
cases, the central nervous system is involved (i.e. neurosarcoidosis), but
hypothalamus-pituitary infiltration by sarcoidosis granulomas is rare
[79]. CH is the second most common pituitary deficit (56%), after
central hypogonadism (88%). One-third of patients have panhypopi-
tuitarism [80]. Langerhans’ cell histiocytosis is a rare disorder char-
acterized by unbridled proliferation of Langerhans’ cell, a type of
dendritic cells. This granulomatous disease varies from self-limited to
fatal forms in which vital functions are compromised [78]. Up to 50%
of patients develop hypopituitarism, with diabetes insipidus being the
most common endocrine manifestation. In about 4% of patients, CH
occurs either alone or in combination with other deficits [81]. We-
gener’s granulomatosis, also known as granulomatosis with polyangitis,
is a rare disorder with unknown etiology, which is characterized by
vasculitis involving small vessels. The pituitary is rarely affected, CH
being reported in half of cases [82].
Finally, CH caused by other granulomatous diseases is extremely
rare, and only anecdotical reports are found in the literature [83–85].
Drugs
Glucocorticoids
Both endogenous and exogenous glucocorticoids are potent in-
hibitors of TSH secretion [86]. Glucocorticoids have been known for
long time to influence TSH secretion, since patients with ACTH-se-
creting microadenomas (thereby without any mass effect on the normal
pituitary) were shown to be associated with CH more often than other
types of microadenomas (see 3.4. Pituitary adenomas). Physiologi-
cally hydrocortisone plays an important role in the diurnal variation of
TSH, with lower concentrations in the morning and higher at night.
This also explains why TSH levels are high in patients with untreated
adrenal insufficiency [87]. High doses of glucocorticoids suppress TSH
in both normal and in hypothyroid subjects. However, a prolonged
administration of high dose glucocorticoids usually does not cause CH
[86].
Dopaminergic drugs
These drugs cause profound inhibition of TSH secretion even at
doses that do not influence blood pressure. Thus, after cessation of
dopamine infusion, there is a rapid reversal of TSH suppression within a
few hours [86,88]. Dopamine and its agonists, such as bromocriptine,
suppress TSH secretion by activating its D2 receptors [86]. The ad-
ministration of dopamine or its derivatives dobutamine and dopex-
amine may cause difficulty in the interpretation of serum concentra-
tions of TSH, as is often the case in CH. If ultrasensitive methods
detecting TSH levels within the range of 0.01mU/L are used, TSH
concentration during treatment with these drugs are usually between
0.08 and 0.4mU/L. These values are clearly different from those
commonly observed in primary hyperthyroidism (TSH lower than
0.01mU/L), but not incompatible with CH [4].
Somatostatin analogs
Somatostatin analogs are mostly used in treatment of acromegaly or
neuroendocrine tumors [89]. They have also demonstrated therapeutic
effectiveness in patients with the syndrome of pituitary resistance to
thyroid hormones and with thyrotropinomas [90,91]. Administration of
somatostatin to healthy volunteers decreases both TSH pulse frequency
and amplitude [86]. Colao et al. stated that prolonged use of soma-
tostatin analogues reduced TSH and its response to stimulus with
thyrotropin-releasing hormone without affecting serum concentrations
of thyroid hormones [89]. In a review of somatostatin analogues in
acromegaly, an incidence of 2% of CH was described [92]. However,
although somatostatin analogues suppress TSH through direct action on
thyrotropes, these effects seem temporary and generally do not promote
the appearance of CH.
Mitotane
Mitotane is a steroidogenesis inhibitor with adrenolytic properties,
which is used to treat adrenocortical cancer. However, it has many side
effects one of which is to affect thyroid function. Daffara et al. studied
14 patients operated for adrenocortical carcinoma on therapeutic ad-
juvant mitotane treatment [93]. They found a number of endocrine-
related changes related to almost all hormone axes and binding pro-
teins, but notably, the changes seen in the hypothalamic-pituitary-
thyroid axis resembled those seen in CH, with reduction of FT4 con-
centrations in the face of normal free triiodothyronine (FT3) and TSH
[93]. This was consistent with an experimental mouse model, where the
secretory capacity of thyrotrophic cells was shown to be inhibited by
therapeutic concentrations of mitotane [94]. In another clinical study
[95] the pattern of CH was confirmed and expanded. Five female pa-
tients with adrenocortical carcinoma (median age 47 years; range
31–65) were treated with mitotane (dosage 1.5 g/day; range 1.0–3.0).
Basal TSH was normal, FT3 concentrations were also normal but below
the median of the reference range, while FT4 concentrations were
below the normal range in all patients. The FT3/FT4 ratio was in the
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upper range in four patients and higher than normal in one patient,
revealing an enhanced T4 to T3 conversion. A blunted TSH response to
TRH was also observed [95].
Bexarotene
Bexarotene is a synthetic compound that represents a new subgroup
of retinoids agents, namely compounds that activate retinoid X re-
ceptors, which can therefore be defined as a rexinoid agent [96–98]. It
is used in the treatment of patients with cutaneous T-cell lymphoma, in
whom it suppresses TSH, as confirmed by in vitro experiments. Bexar-
otene also increases the peripheral metabolism of thyroid hormones by
inducing glucuronyl transferases and sulfotransferases [96]. Conse-
quently, hypothyroid patients on bexarotene require a higher replace-
ment dose (up to two times) of levothyroxine and due to the suppres-
sion, TSH concentrations cannot be used to monitor the treatment dose
[82]. The TSH-suppressing effect was not reported for 13-cis-retinoic
acid (isotretinoin), which is used for severe acne, whereas it was ob-
served in 2 of 4 patients in a pilot study on oral alitretinoin for con-
genital ichthyosis [99].
Cytokines
Cytokines directly affect TSH secretion. For example, tumor necrosis
factor-α does not affect basal TSH secretion in rat thyrotropes, but is
capable to reduce TRH-stimulated TSH secretion [100]. Also, infusion
of interferon-α in normal volunteers results in a 60–70% decrease in
serum TSH within 8–12 h, prior to any significant change in serum
thyroid hormone concentrations [101].
Monoclonal anti-cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA-
4) antibodies
These monoclonal antibodies, by blocking a key immune checkpoint
pathway, are used in the treatment of several neoplasias, such as me-
tastatic renal carcinoma and melanoma. Both ipilimumab and treme-
limumab target the monoclonal anti-cytotoxic T lymphocyte-associated
antigen 4 (CTLA-4) and binds to the same epitope with similar binding
affinity [102]. By blocking CTLA-4, which is a receptor expressed on T-
cells that blocks the immune response after T-cell/antigen-presenting
cell interaction, these monoclonal antibodies enhance T-cell activation
and have antitumor effects. It is still debated whether antitumor actions
stem from an immune response against antigens shared by tumor and
normal self cells, or from activation of specific antitumor T-cells [103].
Ipilimumab has a higher dissociation rate compared with tremeli-
mumab, and consequently, has different pharmacokinetics [102]. The
administration of either ipilimumab or tremelimumab may induce de-
velopment of acute lymphocytic hypophysitis with panhypopituitarism,
CH being the most frequent deficiency (90%) [104]. The incidence of
this adverse effect seems to be dose-dependent [103]. Roughly one in
ten patients on ipilimumab develop hypophysitis, whereas primary
hypothyroidism is much less frequent. Interestingly, the association of
ipilimumab with chemotherapy and radiotherapy seems to prevent
ipilimumab-induced hypophysitis by depletion of immune cells [103].
The clinical presentation of hypophysitis includes headache, and nu-
clear magnetic resonance reveals an enlarged pituitary gland with su-
prasellar convexity, thickening of the stalk and hyperintense hetero-
geneous signal [105–107]. Ipilimumab-induced hypophysitis typically
develops in men in their sixties and affects the anterior lobe [98,106].
Monoclonal anti-programmed cell death-1 receptor (anti-PD-1) antibodies
Rarely, monoclonal anti-programmed cell death-1 receptor (anti-
PD-1) antibodies, such as pembrolizumab and nivolumab cause hypo-
physitis [98,107]. They interfere with the interaction between PD-1 and
its PD-1 ligand, which downregulates T-cells and allow cancer cells to
elude the immune system [108]. The block of either PD-1 or PD-1 li-
gand results in antitumor immunity enhancement both in vitro and in
vivo [103]. Unlike anti-CTLA-4 antibodies, anti-PD1-induced hypo-
physitis is less frequent compared with thyroiditis [109]. The rate of CH
is 1.2% and 0.9% for pembrolizumab and nivolumab, respectively
[107]. Conversely, primary hypothyroidism is reported in up to 20% of
cases [104].
The difference in the rate of hypophysitis between anti-PD-1 anti-
bodies and anti-CTLA-4 antibodies may be explained by different acti-
vation of T-cells and ectopic expression of CTLA-4 in pituitary cells
[109]. As expected, combination of these antibodies increases the risk
of hypophysitis, which have a milder clinical presentation compared to
that caused by monotherapy [109]. In a recent review of combination
therapy clinical trials, hypophysitis was reported in 8% of cases [110].
Conclusions
The present review has provided evidence that acquired CH is less
rare than previously anticipated. In particular, in patients with certain
conditions, such as in those with ipilimumab-induced hypophysitis and
in childhood brain tumors survivors, CH occurs most frequently. The
causes of CH cover direct insults such as traumatic brain injury and
SAH, inflammatory disorders such as primary autoimmune hypophy-
sitis, rare forms of hypersecreting pituitary adenomas, meningitis as
well as treatment-induced forms such as irradiation in survivors of
childhood cancers, and a variety of drugs.
The reported incidences and prevalences are extremely variable in
the different published studies, indicating differences in patient popu-
lations but also in methods for diagnosing CH. The latter is particularly
challenging due to inherent imperfections of quantitatively accurate
measurements of both TSH and FT4. The status of the other pituitary
hormones can further affect these measurements as can a variety of
other factors [4,9,18, cross ref – Central Hypothyroidism, Part II, Ref:
JCTE_2018_65]. Considering the importance of a normal thyroid func-
tion for metabolism and cardiovascular risks [111,112], it is of para-
mount importance to improve the diagnostic procedures for CH, in
particular the measurement methods for FT4 concentrations. Tandem
mass spectroscopy might be an obtainable method, despite the high
price [113]. More studies are clearly needed to improve management of
patients with CH.
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